NeuroTau Inc announces listing of its clinical trial “Evaluation of Tolfenamic Acid in Individuals with Progressive Supranuclear Palsy (PSP)” on ClinicalTrials.gov and intention to begin study in Q1/2021
Nasser H. Zawia was a former dean and the inaugural director of the Interdisciplinary Neuroscience Program (INP) at the University of Rhode Island. He played a co-founding role in the formation of the George and Anne Ryan Institute for Neuroscience.
Dr. Sabbagh is the Camille and Larry Ruvo Endowed Chair for Brain Health and Director of Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas. Dr Sabbagh has dedicated his career to finding a cure for Alzheimer’s and other age-related neurodegenerative diseases.
Mr. Brennan most recently served as the Chief Commercial Officer at Catalyst Pharmaceuticals (NASDAQ: CPRX) and Chief Operating Officer at Edge Therapeutics (NASDAQ: EDGE) where he was responsible for pre-commercialization and launch activities of the company’s lead products targeting rare neurological conditions.
Balanced mix of new substance developments and life cycle management opportunities.